Woodward Diversified Capital

Corent Technology, Inc. is a developer of a cloud management platform designed to analyze software applications and assess their suitability for cloud migration. The company's offerings include SurPaaS Analyzer, which aids in making informed business decisions regarding cloud architecture; SurPaaS Shift, which facilitates the migration of applications while considering scalability and redundancy; and SurPaaS Ops, which supports the deployment and management of applications throughout their lifecycle. Additionally, SurPaaS Transform enables the conversion of web applications into software as a service (SaaS), while SurPaaS Meter helps organizations manage software usage and billing based on consumption. Serving a diverse clientele that includes independent software vendors, enterprises, and managed service providers, Corent Technology is headquartered in Aliso Viejo, California, with operations in Chennai, Amsterdam, and Singapore.

Genelux Corporation is a clinical-stage biopharmaceutical company dedicated to developing innovative oncolytic viral immunotherapies for the treatment of aggressive solid tumors. The company's proprietary technology platform has led to the creation of a diverse pipeline of therapeutic candidates. Its lead product, GL-ONC1, is an attenuated vaccinia virus designed to significantly regress and eliminate various solid tumors while sparing healthy tissues. This candidate also incorporates Green Fluorescent Protein (GFP) to facilitate precise imaging of tumors and metastases, aiding in cancer diagnosis and staging. Currently, GL-ONC1 is undergoing Phase I/II clinical trials in the United States and Europe, with additional trials planned. Early results indicate that GL-ONC1 is well-tolerated, exhibiting minimal side effects and promising signs of anti-tumor efficacy.